CTIS2023-504513-77-00进行中(未招募)1 期
JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU - APHP220919
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •adult patients older than 18 years, - acquired hemophagocytic syndrome, regardless of etiology, defined by the presence of 5 or 6 HLH-2004 criteria or HScore = 200, - admission in the ICU, - need for symptomatic treatment of HS in relation with organ failure, as defined by SOFA score = 4, - Informed consent signed: •by the patient, •Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent in written as per L1111-6,, - Or in an emergency situation and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow)., - The inclusion of women of childbearing potential requires the use of a highly effective contraceptive measure. Contraception should be maintained during treatment and one day after.
排除标准
- •-Moribund, defined by a life expectancy < 48 hours;, -Persons under psychiatric care that would impede understanding of informed consent and optimal treatment and follow-up, -Adults subject to a legal protection measure (guardianship, curatorship and safeguard of justice), -Patients deprived of their liberty by a judicial or administrative decision, -Participation in another interventional research, -Pregnant or lactating patients (women of childbearing potential must have a negative urine or blood Human Chorionic Gonadotropin pregnancy test prior to trial entry);, -No affiliation to health insurance;, -Known hypersensitivity to ruxolitinib;, -Lactose intolerance;, -Hypersensitivity to cellulose, microcrystalline; magnesium stearate; silica, colloidal anhydrous; sodium starch glycolate (Type A); povidone K30; hydroxypropylcellulose 300 to 600 cps,, -Pre-existing decisions of withholding/withdrawing care,, -History of progressive multifocal leukoencephalopathy, -Uncontrolled cutaneous cancer
研究者
相似试验
进行中(未招募)
1 期
Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trialAdults patients having non severe HLHCTIS2024-513173-44-00Assistance Publique Hopitaux De Paris70
尚未招募
2 期
JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care UnitHemophagocytic SyndromesNCT06244862Assistance Publique - Hôpitaux de Paris42
尚未招募
不适用
Influence of JAK inhibitors on the disease-associated network of intestinal immune cells in ulcerative colitisUlcerative ColitisNL-OMON51787eids Universitair Medisch Centrum70
进行中(未招募)
1 期
JeRiCHO: A study to improve the treatment of relapsed or refractory Hodgkin Lymphoma with JAK-inhibitor (Ruxolitinib).relapsed or refractoryHodgkin LymphomaEUCTR2013-003369-33-DEniversity of cologne14
招募中
2 期
JAK INHIBITION IN PRECLINICAL ARTHRITISM05Seropositive rheumatoid arthritisDRKS00032648niversitätsklinikum Erlangen, Medizinische Klinik3, Rheumatologie und Immunologie20
